EXBIO Antibodies

PRODUCT DATA SHEET

1F-584-C100

Monoclonal Antibody to CD79b (mouse) Fluorescein (FITC) conjugated (0.1 mg)

Clone:	HM79
Isotype:	Hamster IgG2
Specificity:	The Armenian hamster monoclonal antibody HM79 recognizes an extracellular epitope of mouse CD79b (CD79 beta, Ig beta), a component of B cell receptor (BCR) complex.
Regulatory Status:	RUO
Immunogen:	Purified CD79a/b (alpha/beta) dimers from WEHI231 cells
Species Reactivity:	Mouse
Negative Species:	Human
Preparation:	The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC.
Concentration:	0.5 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis. Suggested working dilution is 1 microgram/ml. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz

References:

*Gong S, Nussenzweig MC: Regulation of an early developmental checkpoint in the B cell pathway by Ig beta. Science. 1996 Apr 19;272(5260):411-4.
*Teh YM, Neuberger MS: The immunoglobulin (Ig)alpha and Igbeta cytoplasmic domains are independently sufficient to signal B cell maturation and activation in transgenic mice. J Exp Med. 1997 May 19;185(10):1753-8.
*Nagata K, Nakamura T, Kitamura F, Kuramochi S, Taki S, Campbell KS, Karasuyama H: The Ig alpha/Igbeta heterodimer on mu-negative proB cells is competent for transducing signals to induce early B cell differentiation. Immunity. 1997 Oct;7(4):559-70.
*Kouro T, Nagata K, Takaki S, Nisitani S, Hirano M, Wahl MI, Witte ON, Karasuyama H, Takatsu K: Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition. Int Immunol. 2001 Apr;13(4):485-93.
*Fuentes-Pananá EM, Bannish G, Shah N, Monroe J.G.: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol. 2004 Jul 15;173(2):1000-11.
*Fuentes-Pananá EM, Bannish G, van der Voort D, King LB, Monroe J.G.: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. J Immunol. 2005 Feb 1;174(3):1245-52.
*Koyama M, Ishihara K, Karasuyama H, Cordell JL, Iwamoto A, Nakamura T: CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int Immunol. 1997 Nov;9(11):1767-72.
*Maki K, Nagata K, Kitamura F, Takemori T, Karasuyama H: Immunoglobulin beta signaling regulates locus accessibility for ordered immunoglobulin gene rearrangements. J Exp Med. 2000 Apr 17;191(8):1333-40.
*Li Y, Chen F, Putt M, Koo YK, Madaio M, Cambier JC, Cohen PL, Eisenberg RA: B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol. 2008 Sep 1;181(5):2961-72.
*Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T: Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood. 2008 Feb 1;111(3):1497-503.
*Kouro T, Nagata K, Takaki S, Nisitani S, Hirano M, Wahl MI, Witte ON, Karasuyama H, Takatsu K: Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition. Int Immunol. 2001 Apr;13(4):485-93.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz